Story perspectives

Harrow, Inc. Shares Plunge 21% After FDA Drug Approval

3/6/2026

Summary

Story summary

Harrow, Inc. (HROW) shares fell 21% on March 3, 2026, after the U.S. FDA approved its Investigational New Drug application for a Phase 3 trial of TRIESENCE, with the stock at $41.94, down $11.60 from the close of $53.59.
Over past year, Harrow's shares ranged from $20.85 to $54.85.
TRIESENCE is already FDA-approved for intraocular use, and the label expansion targets cataract surgery patients, older individuals who may struggle with eye drop adherence.

1 of 1

Story summary

Harrow, Inc. (HROW) shares fell 21% on March 3, 2026, after the U.S. FDA approved its Investigational New Drug application for a Phase 3 trial of TRIESENCE, with the stock at $41.94, down $11.60 from the close of $53.59.
Over past year, Harrow's shares ranged from $20.85 to $54.85.
TRIESENCE is already FDA-approved for intraocular use, and the label expansion targets cataract surgery patients, older individuals who may struggle with eye drop adherence.